Search clinical trials for: [3H]-TMC435

Total 237 results

Janssen R&D Ireland
Gilead Sciences

Completed

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (COSMOS)

Hepatitis C

United States, Puerto Rico
Dawonmedax Co., Ltd.

Recruiting

Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas

Recurrent Glioblastoma | Recurrent High-grade Glioma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic Oligodendroglioma

Korea, Republic of
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.

Hepatitis C | Viruses
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Janssen R&D Ireland

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C | Genotype 4 Chronic Hepatitis C

Spain
Janssen Research & Development, LLC

Completed

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Hepatitis C, Chronic

Poland, Belgium, Germany, Spain, Canada, Singapore
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (DRAGON)

Hepatitis C, Chronic

Japan
Janssen R&D Ireland

Completed

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Germany, Spain, Belgium, Israel, Portugal, Bulgaria, Romania, Denmark, Greece, Sweden, Canada, Czech Republic, Argentina, Brazil, Austria, Hungary, Switzerland, Puerto Rico, No...
Summit Therapeutics

Completed

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 1)

Clostridioides Difficile Infection

United States, Australia, Greece, Canada, Spain, Brazil, Poland, Korea, Republic of, Argentina, Bulgaria, Hungary, New Zealand, Romania, Russian Federation
Tibotec Pharmaceuticals, Ireland

Completed

TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

Hepatitis C

Belgium
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Medical University of South Carolina
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Diabetes Mellitus, Type 1

United States
University of Cincinnati
National Institute of Mental Health (NIMH); Lindner Center of HOPE

Recruiting

The Role of the Circadian System in Binge Eating Disorder

Binge-Eating Disorder | Circadian Rhythm Disorders

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

France, United Kingdom, Belgium, Germany, Poland, Netherlands
Janssen R&D Ireland

Completed

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

United States, France, United Kingdom, Germany, Spain, Portugal, Canada, Puerto Rico
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
University of California, San Francisco
Janssen Scientific Affairs, LLC

Withdrawn

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

Hepatitis C, Chronic | HIV CDC Category A1

United States
University of Pennsylvania

Suspended

Mendelian Reverse Cholesterol Transport Study

Lipid Metabolism, Inborn Errors | Cholesterol, HDL | Tangier Disease | LCAT Deficiency | Cholesteryl Ester Transfer Protein (CETP) Deficiency

United States
Bristol-Myers Squibb
Janssen Research & Development, LLC

Completed

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Hepatitis C Virus

Argentina, France, United States, Spain, Germany, Hungary
Janssen Research & Development, LLC

Completed

An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

Hepatitis C, Chronic

United States
Peter J. Ruane, M.D.
Janssen Scientific Affairs, LLC

Completed

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C

United States
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Hepatitis C, Chronic

Japan
University Hospital, Basel, Switzerland

Recruiting

Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI) (PRESC1SE-MI)

NSTEMI - Non-ST Segment Elevation MI | Acute Chest Pain

United Kingdom, Switzerland, Spain, Korea, Republic of, United States, Australia, Austria, Finland, Greece, Italy, Romania
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Hepatitis C, Chronic

Japan
University of Connecticut
National Institute on Drug Abuse (NIDA); Yale University; APT Foundation, Inc.

Completed

Secondary HIV Prevention and Adherence Among HIV-infected Drug Users

Risk Behavior | HIV | Medication Adherence

United States
Alessandro Doria
University of Colorado, Denver; University Health Network, Toronto; University... and other collaborators

Not yet recruiting

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (SUGARNSALT)

Heart Failure | Diabetic Nephropathies | Kidney Failure, Chronic | Diabetes Mellitus Type 1

Canada, United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

China
Wolfson Medical Center

Unknown

Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer

ART

Israel
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Chronic Hepatitis C

Belgium, Germany
Janssen R&D Ireland

Completed

A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Hepatitis C, Chronic

Spain, Germany, Poland
Biofrontera Bioscience GmbH

Recruiting

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Acne Vulgaris

United States
Humanity and Health Research Centre
Emory University; Beijing 302 Hospital

Completed

Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects

Chronic Hepatitis C Infection

China
Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
Fundación Canaria Rafael Clavijo para la Investigación...

Completed

Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation

Anaemia

Spain
Université de Sherbrooke
McMaster University; University of Ottawa

Completed

Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7) (GB7)

Type2 Diabetes

Canada
Daiichi Sankyo, Inc.

Completed

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
National Hepatology & Tropical Medicine Research...
Cairo University

Unknown

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (FRI-STC)

Hepatocellular Carcinoma | Hepatitis C, Chronic

Egypt
Kowa Research Institute, Inc.

Completed

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

Healthy

United States
Shinshu University
Kowa Company, Ltd.

Recruiting

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) (TRUTH-DKD)

T2DM (Type 2 Diabetes Mellitus) | Metformin | SGLT2-Inhibitors

Japan
Kowa Research Institute, Inc.

Completed

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

Healthy

United States
Sanofi
Kowa Company, Ltd.

Completed

TOFO Insulin Combination Trial

Type 2 Diabetes Mellitus

Japan
Kowa Research Institute, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NASH

United States, Canada, Spain, Japan, Bulgaria
Kowa Company, Ltd.
Sanofi

Completed

Tofogliflozin GLP-1 Analogue Combination Trial

Type 2 Diabetes Mellitus

Japan
Institut de cancérologie Strasbourg Europe

Withdrawn

Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) (HYACINTHE)

Hematologic Malignancy | COVID19

France
National Institute of Allergy and Infectious Diseases...

Withdrawn

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

HIV Infections | Pregnancy

United States, Puerto Rico, Brazil, Bahamas
University of Debrecen

Completed

Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3) (NEAT-3)

Neuromuscular Blockade

Hungary
Biogen

Completed

Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease (MOBILE)

Parkinson's Disease

Poland, Israel, Serbia
Kanazawa University
Kowa Company, Ltd.

Completed

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Non-alcoholic Fatty Liver Disease

Japan

3

Subscribe